Gilead Sciences reports almost US$900m in Q3 remdesivir sales

[NEW YORK] Remdesivir, a therapeutic to treat Covid-19, boosted third-quarter sales for pharma company Gilead Sciences by nearly US$900 million, according to results released Wednesday by the drugmaker.

The medication, sold under the brand name Veklury, which was originally developed to treat Ebola, has been shown to shorten the recovery time for patients hospitalized with the coronavirus. Gilead reported a 17 per cent jump in third-quarter revenues to US$6.6 billion.

AFP